Morgridge Institute for Research

Enrich Biosystems Joins Cell Manufacturing Research Initiative to Further Advance Cell Therapy Discovery

Retrieved on: 
Monday, August 14, 2023
Emory University, Morgridge Institute for Research, Georgia Tech, Fraunhofer Competence Field Additive Manufacturing, University, University of Puerto Rico at Humacao, NSF, Wallace H. Coulter Department of Biomedical Engineering, National Science Foundation, Cancer, DSM-IV codes, Research, Carol Ann, Biomedical engineering, University of Wisconsin–Madison, Common, Biomedicine, Patient, Cell, Conditional sentence, BioSystems, University of Oregon, Wallace, Kinetics, Pharmaceutical industry

BRANFORD, Conn., Aug. 14, 2023 /PRNewswire-PRWeb/ -- Enrich Biosystems, a pioneering early-stage biotech company developing a unique microfluidics-free cell analysis and isolation technology, today announced it has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT). CMaT is a consortium of universities, companies, and clinical collaborators brought together to develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Launched in 2017 with investment from NSF, the Center aims to revolutionize the treatment of cancer, heart disease, neurological disorders, and other chronic diseases by enabling the broad use of potentially curative therapies utilizing living cells.

Key Points: 
  • Enrich Biosystems has revolutionized cancer cell therapy discovery with its cutting-edge microfluidics-free technology.
  • Enrich technology simplifies the process of cell co-culturing and kinetics profiling to conduct guided capturing based on cell behaviors and functions.
  • "By partnering with the Enrich team, we aim to improve the current processes of discovery and manufacturing for critical cell therapies.
  • "The Enrich team is thrilled and proud to join the CMaT community," said Dong Wang, CEO at Enrich Biosystems.

CSU Releases Findings of Three-Year Research Study on NAVA'S Lakehouse Community

Retrieved on: 
Monday, July 10, 2023
Maintenance, Fatigue, Partnership, International, Built environment, Knowledge building community, CSU, Friends, Health, Overalls, Colorado State University, Journal, Social science, Environmental health, Research, WELL, NAVA, Morgridge Institute for Research, Acoustics, Nature, Sloan, Happiness, Music recording certification, Certification, Environment, Glass, Safety, Nursing, Tourism, Sureserve

DENVER, July 10, 2023 /PRNewswire/ -- NAVA Real Estate Development (NAVA), in partnership with Colorado State University's (CSU) Institute for the Built Environment (IBE), has announced the completion of a three-year research study on Lakehouse, Colorado's first WELL-Certified multifamily residential community. Through the study, which aimed to better understand how thoughtful and sustainable design can influence the health and wellness of occupants, CSU researchers found evidence of increased satisfaction and improved physical and emotional well-being among residents who resided in Lakehouse.

Key Points: 
  • Lakehouse is a 12-story, 196-unit community, located minutes west of downtown Denver in the Sloan's Lake neighborhood and uniquely designed to promote the health and well-being of its residents.
  • Residents reported increased satisfaction with Lakehouse's natural light, air quality, acoustics, safety, on-site fitness equipment and classes, urban farm and community kitchen.
  • In addition to engaging with CSU for the Lakehouse research case study, NAVA has partnered with IWBI to evaluate the potential economic and financial benefits of WELL Certification on projects.
  • For insights and key takeaways from CSU's Jennifer Schill, who led the research, visit https://chhs.source.colostate.edu/residents-healthier-happier-when-livin... .

SHINE Technologies Appoints Experienced Company Builder to Board of Directors

Retrieved on: 
Wednesday, June 7, 2023
Morgridge Institute for Research, University, Lutetium, MBA, Public health, Tomotherapy, University of Wisconsin School of Medicine and Public Health, Shine Technologies, Anesthesiology, Faculty, Growth, Research, GE HealthCare, SHINE, San Diego State University, Nursing

JANESVILLE, Wis., June 7, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced the appointment of Dr. Frederick Robertson to the company's board of directors.

Key Points: 
  • JANESVILLE, Wis., June 7, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced the appointment of Dr. Frederick Robertson to the company's board of directors.
  • Robertson brings a wealth of experience in building companies in the medical device, life science and pharmaceutical industries.
  • He held the role of CEO and director of TomoTherapy, a producer of sophisticated X-ray-based cancer therapy equipment, until the company was acquired in 2011.
  • "This is an exciting time for SHINE as it works to make fusion-driven medical isotopes a reality," Robertson said.

Mission Bio Joins NSF Cell Manufacturing Research Initiative to Advance Cell Therapy Development

Retrieved on: 
Tuesday, March 28, 2023
Product management, Emory University, DNA, Morgridge Institute for Research, Georgia Tech, Fraunhofer Competence Field Additive Manufacturing, University, Senior, University of Puerto Rico School of Dental Medicine, NSF, Wallace H. Coulter Department of Biomedical Engineering, National Science Foundation, Gene editing, Cancer, Cell, Biomedical engineering, Disorder, Marketing, University of Wisconsin–Madison, B cell, Common, Biomedicine, Patient, SAN, University of Oregon, Research, Wallace, Safety, Pharmaceutical industry, Vaccine, Tutoring

SOUTH SAN FRANCISCO, Calif., March 28, 2023 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT), leveraging its Tapestri® Platform to improve analytical assays and cell manufacturing processes. CMaT is a consortium of universities, companies, and clinical collaborators brought together to develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 28, 2023 /PRNewswire/ -- Mission Bio , the pioneer in high-throughput single-cell DNA and multi-omics analysis, has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT), leveraging its Tapestri® Platform to improve analytical assays and cell manufacturing processes.
  • Consortium researchers will utilize Tapestri®'s single-cell multi-omics capabilities to streamline and improve analytical assays that are crucial for assessing quality during various stages of the cell therapy development process.
  • Because Tapestri® enables measurement of genotypic and immunophenotypic attributes at single-cell resolution, it will be particularly useful for early cell therapy development to validate cell engineering techniques.
  • "We're proud to join this collaborative effort across various sectors to advance the field of cell therapy from within the community," said Anjali Pradhan, Senior Vice President of Product Management and Marketing at Mission Bio.

Dr. Sangtae Kim to Lead Verseon's New AI and Data-Science Initiative as CTO

Retrieved on: 
Wednesday, January 12, 2022
Biological engineering, Chemical engineering, Research, CTO, BS, NSF, American Institute of Chemical Engineers, Science, Collection, Ho-Am Prize in Engineering, Morgridge Institute for Research, CEO, American Institute for Medical and Biological Engineering, Drug design, Hereditary angioedema, Government, Eli Lilly, Lists of diseases, Distinguishing, Initiative, Warner–Lambert, Ho-Am Prize in Science, National Academy of Engineering, University of Wisconsin–Madison, American Institute, William O. Baker Award for Initiatives in Research, Drug development, Doctor of Philosophy, National, AI, Verseon, Medicine, National academy, Sang, University, Diabetic retinopathy, Microfluidics, Pharmaceutical industry, Management, Engineering, Purdue University, California Institute of Technology

FREMONT, Calif., Jan. 12, 2022 /PRNewswire/ -- Verseon is pleased to announce the appointment of its new CTO, Dr. Sangtae (Sang) Kim.

Key Points: 
  • FREMONT, Calif., Jan. 12, 2022 /PRNewswire/ -- Verseon is pleased to announce the appointment of its new CTO, Dr. Sangtae (Sang) Kim.
  • Sang, a member of the US National Academy of Engineering , will spearhead expansion of the company's data-science and AI initiatives.
  • Sang's engineering and data-science expertise will both complement and expand Verseon's already significant technological advantages in computer-driven drug design.
  • In recent years he has started research initiatives to use AI for multiple aspects of drug design and development.

WARF announces annual grant figures

Retrieved on: 
Monday, October 25, 2021
Science, Research, University of Wisconsin–Madison, University, Wisconsin Alumni Research Foundation, Invention, Industry, Computer, Innovation, History, Biomedical Research, Trustee, Faculty, Policy, Badger, Information science, Discovery, Investment, COVID-19, Endowment, Health, Therapy, Warf, Autumn, Education, Morgridge Institute for Research, Ministry of Education (Malaysia), Pharmaceutical industry, Management

MADISON, Wis., Oct. 25, 2021 /PRNewswire/ -- The Wisconsin Alumni Research Foundation (WARF) today announced a total of $216.8 million in support for the University of Wisconsin-Madison research enterprise during the 2021-22 academic year. The figure is WARF's largest annual investment in UW-Madison-based research and education in the foundation's history.

Key Points: 
  • WARF is pleased to be part of the solution through our annual grant, additional facility and pandemic support and our everyday work advancing Badger inventions to market."
  • "WARF was founded over nine decades ago by Professor Steenbock to protect and commercialize inventions from UW-Madison," says Dr. James Berbee, Chair of the WARF Board of Trustees.
  • WARF's annual grant continues a tradition of investing in UW-Madison that dates back almost a century.
  • WARF is home to WARF Accelerator advancing promising university technologies, WARF Therapeutics combining world-renowned research and an industry-focused approach to improve value propositions of drug candidates and WARF Ventures which actively invests in startups with UW-Madison technology over two decades.

WARF announces annual grant figures

Retrieved on: 
Monday, October 25, 2021
Science, Research, University of Wisconsin–Madison, University, Wisconsin Alumni Research Foundation, Invention, Industry, Computer, Innovation, History, Biomedical Research, Trustee, Faculty, Policy, Badger, Information science, Discovery, Investment, COVID-19, Endowment, Health, Therapy, Warf, Autumn, Education, Morgridge Institute for Research, Ministry of Education (Malaysia), Pharmaceutical industry, Management

MADISON, Wis., Oct. 25, 2021 /PRNewswire/ -- The Wisconsin Alumni Research Foundation (WARF) today announced a total of $216.8 million in support for the University of Wisconsin-Madison research enterprise during the 2021-22 academic year. The figure is WARF's largest annual investment in UW-Madison-based research and education in the foundation's history.

Key Points: 
  • WARF is pleased to be part of the solution through our annual grant, additional facility and pandemic support and our everyday work advancing Badger inventions to market."
  • "WARF was founded over nine decades ago by Professor Steenbock to protect and commercialize inventions from UW-Madison," says Dr. James Berbee, Chair of the WARF Board of Trustees.
  • WARF's annual grant continues a tradition of investing in UW-Madison that dates back almost a century.
  • WARF is home to WARF Accelerator advancing promising university technologies, WARF Therapeutics combining world-renowned research and an industry-focused approach to improve value propositions of drug candidates and WARF Ventures which actively invests in startups with UW-Madison technology over two decades.

$175 Million Commitment Helps Launch UW–Madison School of Computer, Data & Information Sciences, Support Transformative Mission

Retrieved on: 
Friday, September 17, 2021
Education, Technology, Software, Continuing, Training, University, Wisconsin Alumni Research Foundation, CDIS, School, Student, Multimedia, Cisco Systems, Computer, Computer Sciences, Faculty, Morgridge Institute for Research, CEO, University, Information science, WARF, University of Washington Information School, LMN, Technology, Information school, LMN Architects, Industry, Pharmaceutical industry, Interior design

View the full release here: https://www.businesswire.com/news/home/20210917005387/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210917005387/en/
    The interior of the planned School of Computer, Data & Information Sciences Building at the University of WisconsinMadison will be the center of the campus computer science community.
  • Image Credit - Kahler Slater and LMN Architects
    CDIS brings together UWMadisons highly ranked Computer Sciences and Statistics departments and the Information School.
  • The School of Computer, Data & Information Sciences is a place where our faculty and students will shape the way technology influences and enriches our lives.
  • Tashia and I hope our commitment will inspire others to see the transformative potential of this project and help get it over the finish line.